Equities

Kyorin Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Kyorin Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,681.00
  • Today's Change-16.00 / -0.94%
  • Shares traded50.40k
  • 1 Year change+22.08%
  • Beta0.3083
Data delayed at least 15 minutes, as of Mar 03 2026 04:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 26-Feb-26
Select bar for recommendation details.
Recommendations26-Feb-26
Buy0
Outperform0
Hold1
Sell1
Strong Sell0

Share price forecast in JPY

The one analyst offering a 12 month price target expects Kyorin Pharmaceutical Co Ltd share price to fall to 1,550.00 in the next year from the last price of 1,697.00.
High-8.7%1,550.00
Med-8.7%1,550.00
Low-8.7%1,550.00

Dividends in JPY

In 2025, Kyorin Pharmaceutical Co Ltd reported a dividend of 52.00 JPY, equaling last years dividend. The 2 analysts covering the company expect dividends of 57.00 JPY for the upcoming fiscal year, an increase of 9.62%.
Note: The percentage change is calculated using unrounded (raw) dividend values.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

Kyorin Pharmaceutical Co Ltd reported annual 2025 earnings of 158.17 per share on May 12, 2025.
Average growth rate+16.83%
More ▼

Revenue history & estimates in JPY

KYORIN Holdings, Inc. had revenues for the full year 2025 of 130.09m. This was 8.83% above the prior year's results.
Average growth rate+6.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.